Company
Escient Pharmaceuticals
- Status
- Acquiredas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Escient develops first-in-class small molecule MRGPR inhibitors for immune and neurological applications. It uses state-of-the-art medicinal chemistry and biological tools to develop targeted small molecule therapeutics. Escient was acquired by Incyte for $750M in May 2024.
About the company
- Status notes
- Escient was acquired by Incyte for $750M in May 2024.
Exit
- Acquisition
- $750M, 2024-05$750M
Loading relationship preview